Open-house pharmaceutical discount agreements for Nevirapine, ATC J05AG01

Summary

This is an open-house contract model for non-exclusive, identical and non-negotiable pharmaceutical discount agreements covering Nevirapine (ATC J05AG01). The contracting authority intends to conclude an agreement with every interested pharmaceutical company that meets the requirements; there is no selection decision between competing offers. The earliest contract start date is 1 November 2026, and all agreements end on 31 October 2028. Complete and correct documents submitted by the 3rd day of a month allow the contract to start on the following month’s first day; otherwise, it starts on the first day of the subsequent month. The final date for concluding an agreement is 3 September 2028. Agreements may be terminated with one month’s notice effective at the end of a month and may automatically cease to apply if a competing nationwide or regional discount agreement enters into force. The company must request access to the confidential procurement documents and submit the required signed documents in the permitted format.